reduce basal insulin dose when starting glp-1 receptor agonist Should a patient stop their long-acting (insulin glargine or detemir) a Glucagon-like peptide-1 (GLP-1) agonist, such as liraglutide? Frontiers | GLP−1 receptor agonists

It is one of the most-studied peptides in the animal-model tissue-repair literature

10.1016/j.intimp.2009.08.019 Int Immunopharmacol

Historically, injectable semaglutide was considered more effective due to its higher bioavailability, meaning more medication is absorbed into the bloodstream

Heres what they had to say: Dena Westphalen: The first IV vitamin drips were developed and administered by Dr

10.1007/s00203-017-1459-x Summary Keywords gut microbiota, gastrointestinal diseases, cancer, therapy, dysbiosis Citation Ullah H, Arbab S, Chang C, Bibi S, Muhammad N, Rehman SU, Suleman, Ullah I, Hassan IU, Tian Y and Li K (2025) Gut microbiota therapy in gastrointestinal diseases

Short half-life (~2 hours) Why dosing is built around clean pulses, not steady levels